roscovitine
Small moleculeexperimentalCOVID-19
Seliciclib is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that inhibit multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase or state within the cell cycle of treated cells. Seliciclib is being developed by Cyclacel. This is a phase II, dose ranging, multicenter, randomized, double-blind, placebo-controlled study. — Wikipedia
Clinical trial activity
7 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2006 (NCT00372073)
Timeline
Indications
Mechanism of action
- Cyclin-dependent kinase 1INHIBITOR
CDK1 inhibitor
- Cyclin-dependent kinase 5INHIBITOR
CDK5 inhibitor
- Cyclin-dependent kinase 9INHIBITOR
CDK9 inhibitor
- Cyclin-dependent kinase 2INHIBITOR
CDK2 inhibitor
- Cyclin-dependent kinase 7INHIBITOR
CDK7 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1- Mol. weight
- 354.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSeliciclib ↗
- ChEMBLCHEMBL14762 ↗
Also known as
- 2-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine
- (2r)-2-((6-benzylamino-9-(propan-2-yl)-9h-purin-2-yl)amino)butan-1-ol
- al-39256
- al-39256
- al-39256
- cyc202
- cyc 202
- cyc-202
- cyc-202
- cyc-202
- roscovitine
- roscovitine
- roscovitine
- r-roscovitine
- seliciclib
- seliciclib
- seliciclib
- seliciclib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03774446 | Phase 2 | Nov 2, 2018 | Cedars-Sinai Medical Center |
| NCT02649751 | Phase 2 | Feb 1, 2016 | Cyclacel Pharmaceuticals, Inc., ManRos Therapeutics, University of Western Brittany |
| NCT02160730 | Phase 2 | May 1, 2014 | Cedars-Sinai Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| NCT01333423 | Phase 1 | Sep 1, 2012 | National Institutes of Health (NIH), University of Texas at Houston |
| NCT00761709 | Phase 2 | Jul 1, 2009 | Alcon |
| NCT00999401 | Phase 1 | Apr 1, 2009 | Cyclacel Pharmaceuticals, Inc., Harvard University |
| NCT00372073 | Phase 2 | Jul 1, 2006 | Cyclacel Pharmaceuticals, Inc., Pennsylvania State University |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | For profit | 3 | 2 | 2 | 2006 |
| Cedars-Sinai Medical Center | Academic/Hospital | 2 | 2 | 1 | 2014 |
| Alcon | For profit | 1 | 1 | 1 | 2009 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| ManRos Therapeutics | For profit | 1 | 0 | 1 | 2016 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 0 | 1 | 2014 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2012 |
| Pennsylvania State University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2012 |
| University of Western Brittany | Academic/Hospital | 1 | 1 | 1 | 2016 |
10 organizations
Page 1 / 1